Hodgkin Lymphoma

Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma

Join Robert Chen, MD from City of Hope Comprehensive Cancer Center for this NCCN webinar presentation, Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma.

Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un

What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?

Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment.

Advances in the Management of Classical Hodgkin Lymphoma

Advances in the management of Hodgkin lymphoma (HL) and development of more effective treatment options over the last few decades have led to improvements in 5-year survival rates, with HL considered to be among the most curable of malignancies with modern treatments.

ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?

An awareness of the updated safety and efficacy results from the ECHELON-1 trial will help clinicians determine how to optimally incorporate BV-AVD regimen as fist-line therapy in appropriately selected patients with stage III-IV classical Hodgkin lymphoma.

Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma (JA copy)

The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.

NCCN Guidelines® Insights - Hodgkin Lymphoma, Version 2.2022

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL.

Recorded Presentation from the NCCN Pharmacy Updates: Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment

It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.

NCCN Pharmacy Updates: Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment